Directors duties: Here’s what ASX company directors owe their investors
Some investors may think the only Directors duties are to ‘create shareholder value’. Maybe in their eyes, but not the…
Gorilla Gold Mines (ASX:GG8): Its skyrocketed from a minnow to a $300m company
Gorilla Gold Mines (ASX:GG8) has had a run in 12 months that its shareholders could only have dreamed of. The…
Alvo Minerals finds itself a new Brazilian target
Every now and then in the mining game you meet people with a knack of finding more than one good…
Goodman Group (ASX:GMG): It looks expensive at A$65bn, but can its expansion into Data Centers make it worth its high price?
Goodman Group (ASX:GMG), the ASX’s biggest industrial property player, is making a shift into the world of data centres. On…
Here are 5 ASX resources stocks with a DFS unveiled in the last 12 months!
ASX resources stocks with a DFS (Definitive Feasibility Study) have the best possible chance for investors to profit. Companies in…
How will stocks be impacted by tariffs? Here are 6 victims on the ASX and how they’re responding
How will stocks be impacted by tariffs? Its a long story, but few stocks can say that there’ll be no…
The $3m super tax is coming! If you’re invested in equities, here is how it might impact you
It seems during the next 3 years, the $3m super tax will be officially a thing. Itwas blocked by the…
Northern Star Resources (ASX:NST): The $28bn gold miner that stands above them all
Northern Star Resources (ASX:NST) is by far the largest gold company on the ASX, capped at $28bn as of May…
6 ASX stocks you forgot were listed
Here are 6 ASX stocks you forgot were listed Brisbane Broncos (ASX:BBL) No it is not a mistake. This…
Inghams shares have been volatile in the last 12 months, but better times might be ahead
It has been a while since we last wrote about Inghams shares (ASX:ING) – 8 months to be exact. It…
Its reporting season in New Zealand in May and these 5 ASX companies are about to report annual results
Its always reporting season in New Zealand in May as well as November, because many companies there follow an April…
Immutep (ASX:IMM): Set to commercialise its lung cancer treatment by 2027
Developing a cancer drug is a long journey, but Immutep (ASX:IMM) is more towards the end than the start. A…
The Latest OPEC Production Increase is 411,000 Barrels! Here’s What It Means for Global Oil Prices
The latest OPEC production increase could hit oil prices hard. OPEC (Organisation of the Petroleum Exporting Countries) has decided to…
Labor’s 2025 Win: 5 Stocks Set to Soar Under the New Government
As Australia heads into a new political era with Labor’s win in 2025, investors are paying close attention to the…
This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Phase 3 ASX biotech that is close to unlocking its market opportunity. It is…